Kevin K. Buckbee - Mar 1, 2023 Form 3 Insider Report for AbbVie Inc. (ABBV)

Role: SVP, Controller
Signature: Steven L. Scrogham, attorney-in-fact for Kevin K. Buckbee
Stock symbol: ABBV
Transactions as of: Mar 1, 2023
Transactions value $: $0
Form type: 3
Date filed: 3/10/2023, 04:06 PM
Next filing: Feb 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABBV	Common Stock, $0.01 par value						7.16K	Mar 1, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ABBV	Option (Right to buy)							Mar 1, 2023	Common Stock	13.9K	$93.50	Direct	F2
holding	ABBV	Option (Right to buy)							Mar 1, 2023	Common Stock	9.32K	$105.92	Direct	F3
holding	ABBV	Option (Right to buy)							Mar 1, 2023	Common Stock	7.01K	$144.54	Direct	F4
holding	ABBV	Option (Right to buy)							Mar 1, 2023	Common Stock	6.08K	$149.62	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 6,918 restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. These restricted stock units vest in full on February 17, 2025, and include the right to have stock withheld for tax purposes.
F2	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 4,637 shares on 2/20/2021, as to 4,637 shares on 2/20/2022, and as to 4,637 shares on 2/20/2023.
F3	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,106 shares on 2/18/2022, as to 3,105 shares on 2/18/2023, and will become exercisable as to 3,105 shares on 2/18/2024.
F4	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,335 shares on 2/17/2023, as to 2,335 shares on 2/17/2024 and as to 2,335 shares on 2/17/2025.
F5	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,026 shares on February 16, 2024, as to 2,025 shares on February 16, 2025, and as to 2,025 shares on February 16, 2026.